Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.
Niels W.C.J. van de Donk(Oncode Institute), María‐Victoria Mateos(Hospital Clínico San Carlos), Danielle Trancucci(Centre Hospitalier Universitaire de Nantes), Alfred L. Garfall(University of Pennsylvania), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Lotfi Benboubker, Alfredo Perales‐Puchalt(The Wistar Institute), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Caroline Hodin(Janssen (Belgium)), Laura Rosiñol(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Kaz Groen(Amsterdam University Medical Centers), Katarina Uttervall(Karolinska University Hospital)
Cited by 28
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k